EBMT activity survey 2004 and changes in disease indication over the past 15 years

Bone Marrow Transplantation

Volumn 37, Issue 12, 2006, Pages 1069-1085

  Gratwohl, A ^a   Baldomero, H ^a   Frauendorfer, K ^b   Urbano Ispizua, A ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF ST GALLEN   (Switzerland)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Europe; Hematopoietic stem cell transplantation; Leukemia; Non malignant diseases; Solid tumor; Transplant rates

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW DEPRESSION; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONTROLLED STUDY; DONOR; EUROPE; EWING SARCOMA; GERM CELL TUMOR; GRAFT VERSUS HOST REACTION; HEALTH CARE ORGANIZATION; HEALTH PRACTITIONER; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; KIDNEY CANCER; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MELANOMA; METABOLIC DISORDER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PATIENT COUNSELING; PERIPHERAL BLOOD STEM CELL; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SOFT TISSUE SARCOMA; THALASSEMIA; TIME; TREATMENT INDICATION;

EUROPE; FEMALE; HEALTH CARE SURVEYS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745019089     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705377     Document Type: Article

References (21)

1. Thomas ED. Bone marrow transplantation: A review. Semin Hematol 1999; 36 (Suppl 7): 95-103.
2. Horowitz MM. Uses and growth of hematopoetic cell transplantation. In: Forman SJ, Blume KG, Thomas ED (eds). Hematopoietic Cell Transplantation, 3rd edn. Blackwell Scientific Publishers Inc.: London, New York, 2003, pp 9-15.
3. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895-902.
4. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A, Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002; 100: 2374-2386.
5. Gratwohl A, Passweg J, Baldomero H, Horisberger H, Urbano-Ispizua A, for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Economics, health care systems and utilisation of haematopoietic stem cell transplants in Europe. Br J Haematol 2002; 117: 451-468.
6. Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant 1991; 8: 197-201.
7. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439-449.
8. Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urgano-Ispizua A. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: A report of the EBMT activity survey 2003. Bone Marrow Transplant 2005; 36: 575-590.
9. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000; 111: 6-17.
10. Slavin S. Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation. Lancet 2004; 364: 122-124.
11. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
12. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al., IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
13. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
14. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al., Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 25: 1287-1295.
15. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
16. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al., Inter Groupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
17. Gibson J, Ho PJ, Joshua D. Evolving transplant options for multiple myeloma: Autologous and nonmyeloablative allogeneic. Transplant Proc 2004; 36: 2501-2503.
18. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: A feasibility study. Bone Marrow Transplant 2005; 36: 443-451.
19. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
20. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard risk leukemia. Blood 2002; 100: 761-767.
21. Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E, et al., European Group for Blood and Marrow Transplantation (EBMT). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873-880.